Durable Responses to Thalidomide-Based Drug Therapy for Myelofibrosis With Myeloid Metaplasia
|
|
- Clement Barton
- 5 years ago
- Views:
Transcription
1 ORIGINAL ARTICLE THALIDOMIDE AND MYELOFIBROSIS WITH MYELOID METAPLASIA Durable Responses to Thalidomide-Based Drug Therapy for Myelofibrosis With Myeloid Metaplasia RUBEN A. MESA, MD; MICHELLE A. ELLIOTT, MD; GEORGENE SCHROEDER, MS; AND AYALEW TEFFERI, MD OBJECTIVE: To present the results of a long-term analysis of 2 sequential phase 2 trials of thalidomide (alone or in combination) for palliation of myelofibrosis with myeloid metaplasia (MMM). PATIENTS AND METHODS: We analyzed (March 1999 to August 2003) initial and long-term outcomes from 36 patients with symptomatic MMM who had enrolled in either our thalidomide singleagent trial (n=15) or our trial of low-dose thalidomide (50 mg/d) combined with prednisone (n=21). RESULTS: Among the 36 study patients, 20 (56%) showed some improvement in their clinical course. Response rates for specific end points included improvements in anemia (15 of 36 [42%]), thrombocytopenia (10 of 13 [77%]), or splenomegaly (5 of 30 [17%]). The combination of low-dose thalidomide and prednisone, as opposed to single-agent thalidomide, was better tolerated and more efficacious. After a median follow-up of 25 months (range, months), 10 of 36 patients (28%) showed an ongoing response, including 8 patients in whom protocol treatment has been discontinued for a median of 21 months (range, months). Durable treatment responses were documented for only anemia and thrombocytopenia. Treatment response was not affected by the baseline status of bone marrow fibrosis, angiogenesis, osteosclerosis, cytogenetics, or circulating myeloid progenitor (CD34) cell count. Unusual drug effects, all reversible, included leukocytosis (8 patients) and/or thrombocytosis (6 patients). CONCLUSIONS: Thalidomide (alone or combined with prednisone) is an effective first-line treatment of symptomatic anemia or thrombocytopenia in MMM. Thalidomide-based therapy has the potential to produce durable responses in MMM-associated cytopenias, even after discontinuation of the drug. Mayo Clin Proc. 2004;79(7): AMM = agnogenic myeloid metaplasia; IL = interleukin; MDS = myelodysplastic syndrome; MMM = myelofibrosis with myeloid metaplasia; TNF = tumor necrosis factor Myelofibrosis with myeloid metaplasia (MMM) is a clonal stem cell disease that currently is classified with polycythemia vera and essential thrombocythemia as a chronic myeloproliferative disorder. 1 Clinically, the disease is characterized by progressive anemia, marked splenomegaly, profound constitutional symptoms, cachexia, and risk of transformation into acute leukemia. These clinical features are accompanied by peripheral blood leukoerythroblastosis, intense bone marrow stromal reaction (collagen fibrosis, osteosclerosis, neoangiogenesis), and extramedullary hematopoiesis. Median overall survival of approximately 5 years 2 has not been affected by conventional drug therapy. Furthermore, conventional therapy often is associated with suboptimal alleviation of anemia, splenomegaly, and thrombocytopenia. Splenectomy is a viable option for symptomatic splenomegaly that is unresponsive to cytoreductive agents 3 and is preferred over treatment with splenic irradiation. 4 The latter treatment is effectively applied for control of nonhepatosplenic extramedullary hematopoiesis. 5 Although allogeneic hematopoietic stem cell transplantation is a potentially curative treatment option for MMM, its widespread use is limited by the substantial risk of transplant-related mortality and morbidity, especially in view of the advanced age of most of these patients. 6 Thalidomide, a sedative-hypnotic drug with antiangiogenic 7 and cytokine inhibitory 8 properties, has shown therapeutic activity in a spectrum of hematologic malignancies including multiple myeloma 9,10 and myelodysplastic syndrome (MDS). 11 The presence of florid bone marrow angiogenesis in For editorial comment, see page 857 MMM 12 encouraged the development of several small pilot studies that evaluated the therapeutic value of thalidomide for MMM, used either alone or in combination with other drugs. 20,21 Although these studies have uniformly suggested drug activity to alleviate anemia, thrombocytopenia, and splenomegaly, few data exist on the long-term outcomes of thalidomide-responsive patients with MMM. PATIENTS AND METHODS Our article presents the results of a combined long-term analysis (March 1999 to August 2003) of 2 independent thalidomide-based treatment trials for MMM; preliminary short-term results from these 2 trials have been published previously. 17,20 Both trials and the current study have been reviewed and approved by the Mayo Foundation Institutional Review Board. Diagnosis was according to conventional criteria. 1 Patients with all 3 subtypes of MMM, including agnogenic myeloid metaplasia (AMM), post polycythemic myeloid metaplasia, and post thrombocythemic myeloid metaplasia, were eligible for the study. All study patients underwent pretreatment physical exami- From the Division of Hematology and Internal Medicine (R.A.M., M.A.E., A.T.) and Division of Biostatistics (G.S.), Mayo Clinic College of Medicine, Rochester, Minn. Address reprint requests and correspondence to Ayalew Tefferi, MD, Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN ( tefferi.ayalew@mayo.edu) Mayo Foundation for Medical Education and Research Mayo Clin Proc. July 2004;79(7):
2 nation, baseline laboratory assessment of serum chemistries and circulating hematologic peripheral blood cell counts and serum chemistries, and bone marrow examination using cytogenetic and fluorescence in situ hybridization (FISH) studies to exclude occult cases of t(9;22) (ie, BCR/ABL positive) chronic myeloid leukemia and MDS, both of which may present occasionally with intramedullary fibrosis. DRUG ADMINISTRATION Thalidomide was administered by rigorously adhering to the STEPS (System for Thalidomide Education and Prescribing Safety; Celgene Corp, Warren, NJ) program ( for thalidomide safety. For patients who participated in the first of 2 treatment trials (n=15), oral thalidomide was initiated at a dosage of 200 mg/d with the intention to escalate the dosage to 1000 mg/d if tolerated. Drug toxicity limited the maximal dosage administered in that trial to 400 mg/d. Patients who participated in the second treatment trial (n=21) received a combination of low-dose thalidomide (50 mg/d) and a tapering dosage of prednisone (0.5 mg/kg for 1 month; 0.25 mg/kg for the second month; mg/kg for the third month). Patients who responded after 3 months of combination therapy were treated for an additional 3 months with single-agent low-dose thalidomide (50 mg/d). EVALUATION OF RESPONSE A response in anemia, defined as either an increase in hemoglobin concentration of 2 g/dl or higher or a 50% or greater reduction in red blood cell transfusion requirement, was assessed only in those patients with a baseline hemoglobin value lower than 10 g/dl. Similarly, a response in thrombocytopenia was assessed only in those patients with a baseline platelet count lower than /L and was defined as a 50% or greater increase in platelet count with a minimum count of /L. A response in splenomegaly was defined as a 50% or greater reduction in palpable splenomegaly as measured by the maximum right-angle distance from the left costal margin. Improvements in anemia, thrombocytopenia, or splenomegaly had to be sustained for at least 4 weeks to be considered a positive response. Baseline assessments of bone marrow histology (reticulin fibrosis, osteosclerosis, angiogenesis) and marrow karyotype were performed in all patients. Conventional methods were used to grade bone marrow fibrosis and osteosclerosis. 22 Specialized tests included assessment of pretreatment and posttreatment bone marrow microvessel density (using CD34 immunohistochemistry on marrow vessels and semiquantitative light microscopic estimation 12 ), urinary markers of angiogenesis (basic fibroblast growth factor, vascular endothelial growth factor, thrombospondin 1), peripheral blood myeloid progenitor (CD34 + ) cell count, and nuclear scan (technetium Tc 99m sulfur colloid) assessment of extramedullary hematopoiesis. Toxicity was assessed by the National Cancer Institute Common Toxicity Criteria (version 2.0). ACCRUAL OF FOLLOW-UP DATA AND STATISTICS Complete and current follow-up information was obtained for all patients from both clinical trials. Specifically, information on survival, treatment institution in addition to or other than thalidomide, red blood cell transfusion history, and most recent complete blood cell count were obtained in each instance. Median survival after initiation of thalidomide therapy was defined as the interval from the first date of protocol treatment to either death or last contact. The Kaplan-Meier method was used to estimate survival distributions. 23 A log-rank test was used to assess whether survival differed between responders and nonresponders to thalidomide therapy. For response rates, 95% confidence intervals were calculated. RESULTS The entire study population consisted of 36 patients (24 men) (median age, 65 years; range, years) with MMM (28 patients with AMM, 3 with post polycythemic myeloid metaplasia, 5 with post thrombocythemic myeloid metaplasia). The study included 15 patients from the chronologically first treatment protocol who used singleagent thalidomide 17 and another 21 patients from the subsequent treatment protocol who used the combination of lowdose thalidomide and prednisone. 20 The median time from diagnosis to protocol treatment was 36 months (range, months). At the time of protocol treatment, 10 patients (28%) were high risk, 18 (50%) were intermediate risk, and 8 (22%) were low risk according to the Lille 2 MMM prognostic scoring system (stratifies prognostic risk in MMM patients [into low, intermediate, and high] by the presence of anemia [hemoglobin, <10 g/dl] and/or a markedly abnormal leukocyte count [< /L or > /L]). Treatment was indicated in all patients because of clinically important anemia (hemoglobin, <10 g/dl; 27 patients) and/or symptomatic organomegaly (22 patients). Fifteen patients (42%) were red blood cell transfusion dependent, and 22 patients (61%) had a platelet count lower than /L. Circulating blasts were present in 14 patients (39%). No patients had undergone splenectomy previously, and the spleen was palpable at a median of 12 cm (range, 0-26 cm) below the left costal margin. INITIAL RESPONSES Of the 36 study patients, 20 (56%) had a response in anemia, thrombocytopenia, and/or splenomegaly (Table 1). 884 Mayo Clin Proc. July 2004;79(7):
3 TABLE 1. Comparison of Treatment Responses, Drug Toxicity, and Long-term Outcome Between 2 Thalidomide-Based Treatment Trials in MMM* Thalidomide Thalidomide Combined alone 17 plus prednisone 20 results 95% Confidence (N=15) (N=21) (N=36) intervals (%) Initial responses (responses/eligible patients) 7/15 (47) 13/21 (62) 20/36 (56) Anemia (hemoglobin, <10 g/dl) 2/15 (13) 13/21 (62) 15/36 (42) Thrombocytopenia (platelets, < /L) 4/5 (80) 6/8 (75) 10/13 (77) Palpable splenomegaly 1/12 (8) 4/18 (22) 5/30 (17) 6-35 Major toxicities Toxicity dropout rate 8/15 (53) 0/21 (0) Constipation 9/15 (60) 8/21 (38) Orthostatic symptoms 5/15 (33) 0/21 (0) Fatigue 10/15 (67) 2/21 (10) Neurologic toxicities Grade 1 sensory neuropathy 2/15 (13) 5/21 (24) Grade 2 sensory neuropathy 2/15 (13) 1/21 (5) Decreased hearing 2/15 (13) 0/21 (0) Tremor 3/15 (20) 0/21 (0) Confusion 1/15 (7) 0/21 (0) Depression 1/15 (7) 0/21 (0) Sinus bradycardia 2/15 (13) 0/21 (0) Status Dead 6/15 (40) 8/21 (38) 14/36 (39) Alive 9/15 (60) 13/21 (62) 22/36 (61) Alive and still in remission 3/15 (20) 7/21 (33) 10/36 (28) Therapy discontinued 3/15 (20) 5/21 (24) 8/36 (22) Therapy continued 0/15 (0) 2/21 (10) 2/36 (6) Alive but with progressed disease 6/15 (40) 6/21 (29) 12/36 (33) *Values are number (percentage) unless indicated otherwise. MMM = myelofibrosis with myeloid metaplasia. Five patients had thrombocytopenia at baseline; therefore, the remaining 10 were not evaluable for response. Eight patients had thrombocytopenia at baseline; therefore, the remaining 13 were not evaluable for response. Among the 27 patients with symptomatic anemia (hemoglobin, <10 g/dl), 16 (59%) responded, including 8 who were red blood cell transfusion dependent (Table 2). Of 15 red blood cell transfusion dependent patients, 5 (33%) became transfusion independent. Similarly, all 13 patients with a platelet count lower than /L (< /L in 9 patients) had an increase in their platelet count, which was more than 50% of the baseline value in 10 patients (77%). The response in splenomegaly was not as impressive. Among 32 patients with palpable splenomegaly at treatment registration, only 5 (16%) experienced more than a 40% decrease in the maximum distance of palpable spleen edge from the left costal margin (Table 2). Among all study patients, the attainment of treatment response was not significantly correlated with the pretreatment status of bone marrow fibrosis, osteosclerosis, cytogenetics, or angiogenesis. Furthermore, these bone marrow histological parameters were not significantly affected by treatment in clinically responding patients (Table 3). A systematic measurement of pretreatment and posttreatment blood CD34 count and urinary levels of angiogenic markers, a blood lymphocyte subset analysis, and a radiographic (technetium Tc 99m sulfur colloid) estimation of extramedullary hematopoiesis were performed during the second treatment trial that used combination thalidomide and prednisone therapy. These parameters neither influenced nor accompanied treatment response (data not shown). Thalidomide use was discontinued before completion of scheduled therapy in 10 patients (28%) because of drug toxicities (Table 1). The reasons for subsequent drug discontinuation after trial completion among responders are shown in Table 2. In the first treatment trial, which used single-agent thalidomide therapy, 9 (60%) of the 15 patients were unable to tolerate drug dosages of 200 mg/d or higher. In some of these patients, reduction of the thalidomide dosage to 50 mg/d was associated with better drug tolerance and continued efficacy. In contrast, all but 1 of the 21 patients in the second treatment trial (low-dose thalidomide plus prednisone) were able to complete the first 3 months of treatment. The addition of corticosteroids to thalidomide therapy in the combination trial resulted in only minor and reversible toxicities of hyperglycemia and insomnia. The median duration of treatment among nonresponders was 2.7 months (range, months), whereas all treatment responses occurred during the first 3 months after drug initiation. Unusual drug effects, all reversible, included marked leukocytosis (8 patients), thrombocytosis (6 patients), substantial increase in blood CD34 count (5 patients), and deep venous thrombosis (1 patient). Mayo Clin Proc. July 2004;79(7):
4 TABLE 2. Short-term and Long-term Effects of Thalidomide Therapy in 20 Responding Patients With MMM* Thalidomide effects, short-term Thalidomide effects, long-term Patient No./ age (y)/ MMM Maint Hb PLT Spleen Responses Last Last Last Duration Duration sex type dose Start Max Start Max Start Min Hb PLT Spleen Status Hb WBC PLT of F/U of Rx 1/74/M AMM U 3 U Dead 7 2/58/M AMM Alive /56/F AMM U 4 U Alive /67/F AMM 50 4 U Alive /41/F AMM Alive /65/F AMM Dead /55/M PPMM Alive /78/M AMM Alive /55/M AMM 50 4 U Alive /73/F AMM Alive /74/M AMM 50 2 U Dead /73/M AMM Dead /64/F PPMM Alive /69/M AMM 50 2 U Alive /74/M AMM 50 3 U 1 U Dead /46/M AMM Alive /49/M MMM Alive /66/F AMM 50 4 U Dead /62/M AMM 50 3 U 1 U Alive /73/F PTMM 50 3 U 1 U Alive *Bold entries = patients with unmaintained responses after thalidomide. AMM = agnogenic myeloid metaplasia; = patient s choice (not from toxicity or progression); F/U = follow-up (months); Hb = hemoglobin (g/dl) (units/month listed if patient was red blood cell transfusion dependent); Maint = maintenance; Max = maximum; Min = minimum; MMM = myelofibrosis with myeloid metaplasia; PLT = platelet count ( 10 9 /L); PPMM = post polycythemic myeloid metaplasia; Prog = progression; PTMM = post thrombocythemic myeloid metaplasia; Rx = treatment (months); Spleen = spleen size (cm below the left costal margin by palpation); WBC = white blood cell count ( 10 9 /L). Age at registration. Also undergoing 3-month prednisone taper. LONG-TERM OUTCOMES The median follow-up from the initiation of thalidomidebased therapy is now 25 months (range, months). Twenty-two patients (61%) are still living, whereas 14 have died of disease-related complications. The median survival of patients who responded to treatment has not yet been reached (6 deaths), whereas it was 2.4 years in the nonresponding patients (8 deaths) (difference not significant). Among the 20 patients who responded to treatment, 7 continued receiving thalidomide after completing the planned 6 months of protocol therapy. The median duration of therapy in these 7 patients was 13.1 months (range, months). Two patients are currently receiving low-dose (50 mg/d) thalidomide (for 23.4 and 28.5 months) with evidence of continued response and no evidence of longterm toxicity (Table 2). Reasons for discontinuing thalidomide (at trial completion or after) are outlined in Table 2. Patients who chose to discontinue thalidomide while responding (14 of 20, 70%) did so for various reasons, including expense (initial reimbursement issues subsequently resolved), mild toxicities, or a desire of the patient or physician to assess stability after discontinuing treatment. Analysis of the entire study population discloses 8 patients (22%) who have remained in continued remission for a median of 21 months (range, months) after discontinuation of thalidomide-based protocol therapy. Of note, these patients received no other MMM-directed therapy in the interim, and the reasons for drug discontinuation are listed in Table 2. In addition to these 8 patients, 2 others have remained in remission at 19 and 25 months while receiving maintenance therapy with low-dose thalidomide (50 mg/d). Therefore, the overall long-term response rate for thalidomide-based drug therapy in MMM in the current study was 28% (10 patients). Of note, all but 1 of the longterm treatment responders were diagnosed as having AMM. Durable treatment responses were seen for anemia and thrombocytopenia but not for splenomegaly (Table 2). DISCUSSION The short-term experience with thalidomide-based drug therapy for MMM has been reported previously, and studies that involved 10 or more patients have shown a response rate of 20% to 62% in anemia, 25% to 80% in 886 Mayo Clin Proc. July 2004;79(7):
5 Still Reason for Stable not taking Rx stopping Stable taking Rx TABLE 2. Continued Thalidomide effects, long-term Neutropenia Migraines Leukocytosis Prog thrombocytopenia, and 7% to 30% in splenomegaly. 14,15,17-19 The variable response rates reflect differences in patient selection and in definitions of response. In this article, we describe both the short-term and long-term treatment experiences in 2 sequential trials that used thalidomide to treat MMM-associated symptomatic anemia or splenomegaly. The results indicate that thalidomide definitely has therapeutic activity in MMM and strongly suggest that the addition of prednisone to low doses of thalidomide (50 mg/d) improves drug tolerance and may improve the efficacy of thalidomide in overcoming ineffective hematopoiesis. Also, long-term analysis of the data reveals that approximately 28% of patients with MMM, many with intermediate-risk or high-risk Lille criteria, 24 experience a durable response, in anemia and thrombocytopenia, to thalidomidebased therapy. Patients who responded initially continued to respond, even after discontinuation of the drug. We make no assumption that the natural history of the disease is affected by thalidomide therapy. However, we believe that quality of life is improved in responding patients as a result of decreased transfusion requirement and decreased anemia-related adverse effects. We underscore that the current study was not designed to compare single-agent thalidomide therapy with combined low-dose thalidomide and prednisone therapy. However, in agreement with preliminary observations from other investigators, our data strongly suggest that low-dose thalidomide, especially in combination with prednisone, might be as effective and yet less toxic for treatment of MMM. Obviously, these encouraging preliminary data need to be validated in a controlled study. The combination of corticosteroids and thalidomide has been touted to be superior to thalidomide alone for treatment of multiple myeloma. 25,26 However, in contrast to the experience in multiple myeloma, 27 thalidomide treatment benefit in MMM might not be dose dependent, and a lasting effect may persist even after the drug is discontinued. The latter observation is the most intriguing aspect of our research and is not easily explained. Despite this encouraging treatment experience, the mechanism of action of thalidomide in MMM is an enigma. Remember that MMM is a clonal stem cell disease that is accompanied by a cytokine-mediated bone marrow stromal reaction (collagen fibrosis, osteosclerosis, angiogenesis) and ineffective hematopoiesis. 1 Both angiogenesis 12 and tumor necrosis factor α (TNF-α) have been implicated in the pathogenesis of MMM, and the latter may be particularly detrimental to effective erythropoiesis in both MMM 28 and MDS. 29 Therefore, it is tempting to attribute the observed effects of thalidomide to its antiangiogenic and anti TNF-α properties. 7,8 In this regard, the demonstrated activity of thalidomide in MDS 11 and the recent evidence of antidisease activity by etanercept, a soluble TNF-α receptor antagonist, in MMM 30 support a mechanism of drug action that is linked to TNF-α. However, regarding angiogenesis, our study showed no favorable effect of thalidomide on angiogenesis evaluated by both assessment of bone marrow microvessel density and measurement of urinary concentrations of angiogenic cytokines. Similarly, Grossi et al 16 found no correlation between treatment response to thalidomide in MMM and the levels of several angiogenic cytokines (vascular endothelial growth factor and its receptor or transforming growth factor β). Obviously, continued assessment of bone marrow angiogenesis in longterm treatment responders is necessary to validate these preliminary impressions of an angiogenesis-independent mechanism of action. Alternatively, thalidomide may facilitate effective hematopoiesis (thus accounting for an improvement in anemia and thrombocytopenia) through its immunomodulatory properties. Thalidomide costimulates T-lymphocyte proliferation, 31 inducing Th2 cytokine (interleukin [IL] 4 and IL-5) but not Th1 cytokine (interferon γ) production 32 ; IL-4 synergizes with stem cell factor and other cytokines to enhance effective hematopoiesis, 33,34 whereas both interferon γ and TNF-α produce the opposite effect, possibly by promoting programmed cell death. 35 Therefore, drug- Mayo Clin Proc. July 2004;79(7):
6 TABLE 3. Intramedullary Effects of Thalidomide Among Responding Patients With MMM* Reticulin fibrosis (grade 0-4) Angiogenesis (grade 1-4) Response Cellularity (%) Patient Karyotype No. Hb PLT Spleen Time 0 6 mo Time 0 6 mo Time 0 6 mo Time 0 6 mo 1 60 NA 3 NA 4 NA 45,XY[20] NA ,XY,13q-[8/10]/ 46,XY,13q-[15/20]/ 46,XY[2/20] 46,XY[5] ,XX[20] 46,XX,t(1;6)[6]/ 46,XX[14] ,XX,13q-[4]/ 46,XX,13q-[2]/ 46,XX[16] 46,XX[18] ,XX[20] 46,XX[20] NA 2 NA NA NA Complex NA ,XY,18P+[20] 46,XY,18P+[20] ,XY[20] 46,XY[20] ,XY[20] 46,XY[20] ,XX,t(1;10)[8]/ NA 46,XX[12] ,XY[20] 46,XY[20] ,XX,20q-[16]/ 46,XX,20q-[6]/ 46,XX[4] 46,XX[6] ,XY[20] 46,XY[20] ,XY,20q-[17]/ 46,XY,20q-[2]/ 46,XY[3] 46,XY[18] ,XY[20] 46,XY[20] ,XY[20] 46,XY[20] Complex Complex 32 5 NA 4 NA 4 NA NA NA ,XX[20] 46,XX[20] *Bold entries = patients (n=8) with unmaintained responses to thalidomide-based treatment. Complex = >3 structural abnormalities; Hb = hemoglobin; MMM = myelofibrosis with myeloid metaplasia; NA = not available; PLT = platelet count. G-banded karyotype on 20 metaphases from bone marrow aspirate when available. induced phenotypic shift in T-lymphocyte subsets might conceivably contribute to the observed clinical benefit, especially in light of the observation that MMM may display a quantitatively altered lymphocyte population with an increase in cytotoxic T cells (CD3 + /CD56 + ). 36 Furthermore, similar cytokine-mediated mechanisms also may be responsible for the occasional occurrence of disseminated extramedullary hematopoiesis 37 as well as potentially detrimental drug-induced myeloproliferation seen in thalidomide-treated patients with MMM. 38 Nevertheless, a more systematic study is required before accepting or refuting any of these possible drug mechanisms of action. Thrombosis has been identified as an important adverse effect of thalidomide-based drug therapy in multiple myeloma, especially when the drug has been combined with either chemotherapy or corticosteroids. 39,40 Because thrombosis is a well-established disease-associated risk in chronic myeloproliferative diseases, the patients in our study were closely monitored for this complication, and fortunately only 1 case of deep venous thrombosis was documented. Therefore, we currently are not inclined to use prophylactic anticoagulant therapy during treatment of MMM with thalidomide. This and other thalidomide-associated drug adverse effects might be effectively addressed in the future by the development of thalidomide analogues that are more potent and yet less toxic than the parent drug. One of these agents, CC-5013, has shown notable activity in the treatment of both multiple myeloma 41 and MDS. 42 Pilot trials with this agent in MMM are planned to begin soon at our institution and elsewhere. CONCLUSIONS Thalidomide used alone or in combination with prednisone may be considered an effective first-line treatment of symptomatic anemia or thrombocytopenia in MMM. Thalidomide-based therapy has the potential to produce du- 888 Mayo Clin Proc. July 2004;79(7):
7 rable responses in MMM-associated cytopenias, even after thalidomide is discontinued. We acknowledge the Celgene Corporation (Warren, NJ) for providing thalidomide and financial support for the administration costs of both clinical trials. REFERENCES 1. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342: Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996;88: Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood. 2000;95: Elliott MA, Chen MG, Silverstein MN, Tefferi A. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. Br J Haematol. 1998;103: Koch CA, Li C-Y, Mesa RA, Tefferi A. Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment. Mayo Clin Proc. 2003;78: Guardiola P, Anderson JE, Bandini G, et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood. 1999;93: D Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91: Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mrna degradation. J Exp Med. 1993;177: Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma [published correction appears in N Engl J Med. 2000;342:364]. N Engl J Med. 1999;341: Rajkumar SV, Fonseca R, Dispenzieri A, et al. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc. 2000;75: Raza A, Meyer P, Dutt D, et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood. 2001;98: Mesa RA, Hanson CA, Rajkumar SV, Schroeder G, Tefferi A. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood. 2000;96: Pozzato G, Zorat F, Nascimben F, Comar C, Kikic F, Festini G. Thalidomide therapy in compensated and decompensated myelofibrosis with myeloid metaplasia [letter]. Haematologica. 2001;86: Piccaluga PP, Visani G, Pileri SA, et al. Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia: a pilot study. Leukemia. 2002;16: Merup M, Kutti J, Birgergard G, et al, Swedish National Study Group on Chronic Myeloproliferative Disorders. Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia. Med Oncol. 2002;19: Grossi A, Gavazzi S, Biscardi M, et al. Thalidomide therapy effects on angiogenic growth factors (VEGF, TGF-β) and KDR expression in myeloid metaplasia with myelofibrosis [abstract]. Blood. 2002;100(pt 2):346b. Abstract Elliott MA, Mesa RA, Li CY, et al. Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol. 2002;117: Canepa L, Ballerini F, Varaldo R, et al. Thalidomide in agnogenic and secondary myelofibrosis. Br J Haematol. 2001;115: Barosi G, Grossi A, Comotti B, Musto P, Gamba G, Marchetti M. Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 2001;114: Mesa RA, Steensma DP, Pardanani A, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood. 2003;101: Visani G, Mele A, Malagola M, Isidori A, Finelli C, Piccaluga PP. Sequential combination of thalidomide and erythropoietin determines transfusion independence and disease control in idiopathic myelofibrosis previously insensitive to both drugs used as single agents [letter]. Leukemia. 2003; 17: Yoon SY, Li CY, Mesa RA, Tefferi A. Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 1999;106: Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;58: Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996;88: Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol. 2003;21: Rajkumar SV, Hayman S, Fonseca R, et al. Thalidomide plus dexamethasone (Thal/Dex) and thalidomide alone (Thal) as first line therapy for newly diagnosed myeloma (MM) [abstract]. Blood. 2000;96(pt 1):168a. Abstract Neben K, Moehler T, Benner A, et al. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res. 2002;8: Le Bousse-Kerdiles MC, Souyri M, Smadja-Joffe F, Praloran V, Jasmin C, Ziltener HJ. Enhanced hematopoietic growth factor production in an experimental myeloproliferative syndrome. Blood. 1992;79: Sawanobori M, Yamaguchi S, Hasegawa M, et al. Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes. Leuk Res. 2003;27: Steensma DP, Mesa RA, Li CY, Gray L, Tefferi A. Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study. Blood. 2002;99: Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med. 1998; 187: McHugh SM, Rifkin IR, Deighton J, et al. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol. 1995;99: Keller U, Aman MJ, Derigs G, Huber C, Peschel C. Human interleukin- 4 enhances stromal cell-dependent hematopoiesis: costimulation with stem cell factor. Blood. 1994;84: Sonoda Y, Kimura T, Sakabe H, et al. Human FLT3 ligand acts on myeloid as well as multipotential progenitors derived from purified CD34+ blood progenitors expressing different levels of c-kit protein. Eur J Haematol. 1997;58: Selleri C, Sato T, Anderson S, Young NS, Maciejewski JP. Interferongamma and tumor necrosis factor-alpha suppress both early and late stages of hematopoiesis and induce programmed cell death. J Cell Physiol. 1995;165: Cervantes F, Hernandez-Boluda JC, Villamor N, Serra A, Montserrat E. Assessment of peripheral blood lymphocyte subsets in idiopathic myelofibrosis. Eur J Haematol. 2000;65: Khaldoyanidi S, Sikora L, Broide DH, Rothenberg ME, Sriramarao P. Constitutive overexpression of IL-5 induces extramedullary hematopoiesis in the spleen. Blood. 2003;101: Tefferi A, Elliott MA. Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia [letter]. Blood. 2000;96: Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 2001;98: Cavo M, Zamagni E, Cellini C, et al. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood. 2002;100: Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002;100: List AF, Kurtin SE, Glinsmann-Gibson BJ, et al. High erythropoietic remitting activity of the immunomodulatory thalidomide analog, CC5013, in patients with myelodysplastic syndrome (MDS) [abstract]. Blood. 2002;100(pt 1):96a. Abstract 353. Mayo Clin Proc. July 2004;79(7):
Primary myelofibrosis (PMF) is a hematologic malignancy
Brief Report Mature Survival Data for 176 Patients Younger Than With Primary Myelofibrosis Diagnosed Between 1976 and 5: Evidence for Survival Gains in Recent Rakhee Vaidya, MBBS; Sergio Siragusa, MD;
More informationNew Therapies for MPNs
Pomalidomide and IMIDS in Myelofibrosis New Therapies for MPNs Fourth International Workshop on CML and MPN Natchez Louisiana Ruben A. Mesa, MD Professor of Medicine Mayo Clinic College of Medicine Director
More informationTransplants for MPD and MDS
Transplants for MPD and MDS The question is really who to transplant, with what and when. Focus on myelofibrosis Jeff Szer Royal Melbourne Hospital Myelodysplasia Little needs to be said Despite new therapies
More informationASH 2013 Analyst & Investor Event
ASH 2013 Analyst & Investor Event December 9, 2013 John A. Scarlett, MD President & CEO Forward-Looking Statements Except for the historical information contained herein, this presentation contains forward-looking
More informationMyelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data
Instructions for Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data (Form 2114) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Myelodysplasia/Myeloproliferative
More informationWelcome to Master Class for Oncologists. Session 3: 9:15 AM - 10:00 AM
Welcome to Master Class for Oncologists Session 3: 9:15 AM - 10:00 AM Miami, FL December 18, 2009 Myeloproliferative Neoplasms: Bringing Order to Complexity and Achieving Optimal Outcomes Speaker: Andrew
More informationLondon Cancer. Myelofibrosis guidelines. August Review August Version v1.0. Page 1 of 12
London Cancer Myelofibrosis guidelines August 2013 Review August 2013 Version v1.0 Page 1 of 12 CONTENTS 1. DIAGNOSIS... 3 1a. BCSH (2012)... 3 1b. WHO (2009) diagnostic criteria for PMF:... 4 2. MOLECULAR
More informationChronic Idiopathic Myelofibrosis (CIMF)
Chronic Idiopathic Myelofibrosis (CIMF) CIMF Synonyms Agnogenic myeloid metaplasia Myelosclerosis with myeloid metaplasia Chronic granulocytic-megakaryocytic myelosis CIMF Megakaryocytic proliferation
More informationCLINICAL POLICY DEPARTMENT: Medical Management DOCUMENT NAME: JakafiTM REFERENCE NUMBER: NH.PHAR.98
PAGE: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationMyelodysplastic Syndromes Myeloproliferative Disorders
Myelodysplastic Syndromes Myeloproliferative Disorders Myelodysplastic Syndromes characterized by maturation defects that are associated with ineffective hematopoiesis and a high risk of transformation
More informationWALDENSTROM S macroglobulinemia (WM) is a
Treatment of Waldenstrom s Macroglobulinemia With Thalidomide By Meletios A. Dimopoulos, Athanassios Zomas, Nora A. Viniou, Vassiliki Grigoraki, Eleni Galani, Charis Matsouka, Olga Economou, Nikolaos Anagnostopoulos,
More informationMyelofibrosis Stem cell transplantation for myelofibrosis: a report from two Canadian centers
(23) 32, 35 4 & 23 Nature Publishing Group All rights reserved 268-3369/3 $25. www.nature.com/bmt Myelofibrosis Stem cell transplantation for myelofibrosis: a report from two Canadian centers A Daly 1,
More informationMDS-004 Study: REVLIMID (lenalidomide) versus Placebo in Myelodysplastic Syndromes with Deletion (5q) Abnormality
MDS-4 Study: REVLIMID (lenalidomide) versus Placebo in Myelodysplastic Syndromes with Deletion (5q) Abnormality TABLE OF CONTENTS Section 1. Executive Summary Section 2. Background Section
More informationCase Workshop of Society for Hematopathology and European Association for Haematopathology
Case 148 2007 Workshop of Society for Hematopathology and European Association for Haematopathology Robert P Hasserjian Department of Pathology Massachusetts General Hospital Boston, MA Clinical history
More informationMDS 101. What is bone marrow? Myelodysplastic Syndrome: Let s build a definition. Dysplastic? Syndrome? 5/22/2014. What does bone marrow do?
101 May 17, 2014 Myelodysplastic Syndrome: Let s build a definition Myelo bone marrow Gail J. Roboz, M.D. Director, Leukemia Program Associate Professor of Medicine What is bone marrow? What does bone
More informationJAK inhibitors in Phmyeloproliferative
Disclosures for A Pardanani Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory Board TargeGen, Cytopia/YM BioSciences, PharmaMar None None None None None Presentation
More informationSmoldering Myeloma: Leave them alone!
Smoldering Myeloma: Leave them alone! David H. Vesole, MD, PhD Co-Director, Myeloma Division Director, Myeloma Research John Theurer Cancer Center Hackensack University Medical Center Prevalence 1960 2002
More informationML Tanner 1, CK Hoh 2, A Bashey 3, P Holman 3, C Sun 3, HE Broome 4, T Lane 4, ED Ball 3 and E Carrier 3. Summary:
(2003) 32, 581 585 & 2003 Nature Publishing Group All rights reserved 0268-3369/03 $25.00 www.nature.com/bmt Myelofibrosis FLAG chemotherapy followed by allogeneic stem cell transplant using nonmyeloablative
More informationFocus on aggressive polycythemia vera
Focus on aggressive polycythemia vera Jerry L. Spivak, MD Professor of Medicine and Oncology Director, the Johns Hopkins Center for the Chronic Myeloproliferative Disorders Johns Hopkins University School
More informationPomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma. Lacy MQ et al. J Clin Oncol 2009;27(30):
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma Lacy MQ et al. J Clin Oncol 2009;27(30):5008-14. Introduction A curative therapy for multiple myeloma (MM) does
More informationDisclosures for Ayalew Tefferi
Disclosures for Ayalew Tefferi Principal investigator role Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory Board Janssen, Geron, Celgene, Sanofi-Aventis, Gilead Sciences, Incyte
More informationDisclosures. Myeloproliferative Neoplasms: A Case-Based Approach. Objectives. Myeloproliferative Neoplasms. Myeloproliferative Neoplasms
Myeloproliferative Neoplasms: A Case-Based Approach Disclosures No conflicts of interests regarding the topic being presented Adam M. Miller, MD PGY-4 Resident Physician Department of Pathology and Laboratory
More informationEvaluation of Angiogenesis in Idiopathic Myelofibrosis with CD31 and CD34 by Light Microscope and Computer-Aided Image Analysis System.
Evaluation of Angiogenesis in Idiopathic Myelofibrosis with CD31 and CD34 by Light Microscope and Computer-Aided Image Analysis System. Subuh Salim AL -Mudallal 1 FICMS, Mustapha Abdul-Wahid Mukeef 2 MSc.
More informationStifel Nicolaus 2013 Healthcare Conference. John Scarlett, M.D. Chief Executive Officer September 11, 2013
Stifel Nicolaus 2013 Healthcare Conference John Scarlett, M.D. Chief Executive Officer September 11, 2013 1 forward-looking statements Except for the historical information contained herein, this presentation
More informationMyeloproliferative Disorders: Diagnostic Enigmas, Therapeutic Dilemmas. James J. Stark, MD, FACP
Myeloproliferative Disorders: Diagnostic Enigmas, Therapeutic Dilemmas James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS
More informationPresenter Disclosure Information
Welcome to Master Class for Oncologists Session 3: 2: PM 3:3 PM Pasadena, CA May 1, 21 Myeloproliferative Neoplasms 21 Speaker: Ayalew Tefferi Mayo Clinic, Rochester, MN Presenter Disclosure Information
More informationJAK2 Inhibitors for Myeloproliferative Diseases
JAK2 Inhibitors for Myeloproliferative Diseases Srdan (Serge) Verstovsek M.D., Ph.D. Associate Professor Department of Leukemia University of Texas MD Anderson Cancer Center Houston, Texas, USA Myeloproliferative
More informationAllogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Policy Specific Section:
Medical Policy Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Type: Medical Necessity and Investigational / Experimental Policy Specific Section:
More informationHematopoietic Cell Transplantation for Myelofibrosis. Outline
Hematopoietic Cell Transplantation for Myelofibrosis H.Joachim Deeg MD Fred Hutchinson Cancer Research Center & University of Washington, Seattle WA Great Debates, NY, 4/28/2012 Outline Rationale for hematopoietic
More informationHeme 9 Myeloid neoplasms
Heme 9 Myeloid neoplasms The minimum number of blasts to diagnose acute myeloid leukemia is 5% 10% 20% 50% 80% AML with the best prognosis is AML with recurrent cytogenetic abnormality AML with myelodysplasia
More informationA.M.W. van Marion. H.M. Lokhorst. N.W.C.J. van de Donk. J.G. van den Tweel. Histopathology 2002, 41 (suppl 2):77-92 (modified)
chapter 4 The significance of monoclonal plasma cells in the bone marrow biopsies of patients with multiple myeloma following allogeneic or autologous stem cell transplantation A.M.W. van Marion H.M. Lokhorst
More informationThis was a multicenter study conducted at 11 sites in the United States and 11 sites in Europe.
Protocol CAM211: A Phase II Study of Campath-1H (CAMPATH ) in Patients with B- Cell Chronic Lymphocytic Leukemia who have Received an Alkylating Agent and Failed Fludarabine Therapy These results are supplied
More informationChronic Myeloproliferative Disorders
1 Chronic Myeloproliferative Disorders 15th 9 April2015 Polycythemia vera Essential thrombocythemia Idiopathic primary myelofibrosis 2 Learning objectives To appreciate types of polycythaemia (erythrocytosis)
More informationMyelofibrosis a Reference Guide for Journalists
Myelofibrosis a Reference Guide for Journalists What Is Myelofibrosis? Myelofibrosis is an uncommon blood cancer characterized by bone marrow scarring (fibrosis), enlarged spleen (splenomegaly), potential
More informationMultiple Myeloma Updates 2007
Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from
More informationMyteloproliferative Disorders Research Paper
Myteloproliferative Disorders Research Paper Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study Jean-François Abgrall Isabelle
More informationMyeloid neoplasms. Early arrest in the blast cell or immature cell "we call it acute leukemia" Myoid neoplasm divided in to 3 major categories:
Myeloid neoplasms Note: Early arrest in the blast cell or immature cell "we call it acute leukemia" Myoid neoplasm divided in to 3 major categories: 1. AML : Acute myeloid leukemia(stem cell with myeloid
More informationIf unqualified, Complete remission is considered to be Haematological complete remission
Scroll right to see the database codes for Disease status and Response Diagnosis it refers to Disease status or response to treatment AML ALL CML CLL MDS or MD/MPN or acute leukaemia secondary to previous
More informationPolycthemia Vera (Rubra)
Polycthemia Vera (Rubra) Polycthemia Vera (Rubra) Increased red cells Clonal Myeloid lineages also increased 2-13 cases per million Mean age: 60 years Sites of Involvement Bone marrow Peripheral blood
More informationJeanne Palmer, MD Mayo Clinic, Arizona
Setting the stage for Transplant in MPN Jeanne Palmer, MD Mayo Clinic, Arizona What will be covered What is a bone marrow transplant? When to start thinking about bone marrow transplant Timing of transplant
More informationClinical Policy: Thalidomide (Thalomid) Reference Number: PA.CP.PHAR.78 Effective Date: 09/11 Last Review Date: 04/18
Clinical Policy: (Thalomid) Reference Number: PA.CP.PHAR.78 Effective Date: 09/11 Last Review Date: 04/18 Revision Log Description The intent of the criteria is to ensure that patients follow selection
More informationA Phase 1 Trial of Lenalidomide (REVLIMID ) With Bortezomib (VELCADE ) in Relapsed and Refractory Multiple Myeloma
A Phase 1 Trial of Lenalidomide (REVLIMID ) With Bortezomib (VELCADE ) in Relapsed and Refractory Multiple Myeloma P.G. Richardson, 1 R. Schlossman, 1 N. Munshi, 1 D. Avigan, 2 S. Jagannath, 3 M. Alsina,
More informationMayo Clinic Treatment Strategy in Essential Thrombocythemia, Polycythemia Vera and Myelofibrosis 2013 Update
Mayo Clinic Treatment Strategy in Essential Thrombocythemia, Polycythemia Vera and Myelofibrosis 2013 Update Ayalew Tefferi Mayo Clinic, Rochester, MN 0 20 40 60 80 100 Percent Survival in 337 Mayo Clinic
More informationBlood Cancers. Blood Cells. Blood Cancers: Progress and Promise. Bone Marrow and Blood. Lymph Nodes and Spleen
Blood Cancers: Progress and Promise Mike Barnett & Khaled Ramadan Division of Hematology Department of Medicine Providence Health Care & UBC Blood Cancers Significant health problem Arise from normal cells
More informationWHO Update to Myeloproliferative Neoplasms
WHO Update to Myeloproliferative Neoplasms Archana M Agarwal, MD, Associate Professor of Pathology University of Utah Department of Pathology/ARUP Laboratories Myeloproliferative Neoplasms The categories
More informationSafety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
original article Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis Srdan Verstovsek, M.D., Ph.D., Hagop Kantarjian, M.D., Ruben A. Mesa, M.D., Animesh D. Pardanani, M.B., B.S.,
More informationIf unqualified, Complete remission is considered to be Haematological complete remission
Scroll right to see the database codes for Disease status and Response Diagnosis it refers to Disease status or response to treatment AML ALL CML CLL MDS or MD/MPN or acute leukaemia secondary to previous
More informationHCT for Myelofibrosis
Allogeneic HSCT for MDS and Myelofibrosis Sunil Abhyankar, MD Professor Medicine, Medical Director, Pheresis and Cell Processing University of Kansas Hospital BMT Program April 27 th, 213 HCT for Myelofibrosis
More informationMyeloproliferative Disorders - D Savage - 9 Jan 2002
Disease Usual phenotype acute leukemia precursor chronic leukemia low grade lymphoma myeloma differentiated Total WBC > 60 leukemoid reaction acute leukemia Blast Pro Myel Meta Band Seg Lymph 0 0 0 2
More informationJAKAFI (ruxolitinib phosphate) oral tablet
JAKAFI (ruxolitinib phosphate) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationStifel Healthcare Conference John Scarlett, M.D. Chief Executive Officer November 19, 2014
Stifel Healthcare Conference 2014 John Scarlett, M.D. Chief Executive Officer November 19, 2014 1 forward-looking statements Except for statements of historical fact, the statements during this presentation
More informationTHE ITALIAN EXPERIENCE
MYELOFIBROSIS THE ITALIAN EXPERIENCE Giovanni Barosi IRCCS Policlinico S. Matteo. Pavia. Italy Angers, 1-3 October 2004 Myelofibrosis in the eighties A poorly characterized biological syndrome Heterogeneity
More information74y old Female with chronic elevation of Platelet count. August 18, 2005 Faizi Ali, MD Hematopathology Fellow
74y old Female with chronic elevation of Platelet count August 18, 2005 Faizi Ali, MD Hematopathology Fellow Clinical History Patient is a 74y old otherwise healthy Caucasian female with no major complaint
More informationMDS: Who gets it and how is it diagnosed?
MDS: Who gets it and how is it diagnosed? October 16, 2010 Gail J. Roboz, M.D. Director, Leukemia Program Associate Professor of Medicine Weill Medical College of Cornell University The New York Presbyterian
More informationBone marrow histopathology in Ph - CMPDs. - the new WHO classification - Juergen Thiele Cologne, Germany
Bone marrow histopathology in Ph - CMPDs - the new WHO classification - Juergen Thiele Cologne, Germany Current issues in MPNs concerning morphology 1.Prodromal stages of disease 2.Impact of histopathology
More informationDisclosure BCR/ABL1-Negative Classical Myeloproliferative Neoplasms
Disclosure BCR/ABL1-Negative Classical Myeloproliferative Neoplasms Sonam Prakash declares affiliation with Incyte Corporation: Advisor for Hematopathology Publications Steering Committee Sonam Prakash,
More informationPolycythemia Vera and other Myeloproliferative Neoplasms. A.Mousavi
Polycythemia Vera and other Myeloproliferative Neoplasms A.Mousavi Chronic MPNs Multipotent hematopoietic progenitor cell is origin. Overproduction of one or more formed element of blood cells without
More informationJune Ruxolitinib for the second-line treatment of myelofibrosis (IPSS intermediate LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Ruxolitinib for the second-line treatment of myelofibrosis (IPSS intermediate risk-1 or above) Ruxolitinib for the second-line treatment of myelofibrosis (IPSS
More information37 Novel Therapies for
37 Novel Therapies for Multiple Myeloma Abstract: Current standard of management for newly diagnosed multiple myeloma are continuously evolving due to the advent of a number of novel agents with different
More informationD.J. White MD MSc,* N. Paul PhD, D.A. Macdonald MD,* R.M. Meyer MD, and L.E. Shepherd MD ORIGINAL ARTICLE ABSTRACT KEY WORDS 1.
ORIGINAL ARTICLE Addition of lenalidomide to melphalan in the treatment of newly diagnosed multiple myeloma: the National Cancer Institute of Canada Clinical Trials Group MY.11 trial D.J. White MD MSc,*
More informationLa lenalidomide: meccanismo d azione e risultati terapeutici. F. Ferrara
La lenalidomide: meccanismo d azione e risultati terapeutici F. Ferrara MDS: new treatment goals Emerging treatment options expected to facilitate shift from supportive care to active therapy in MDS New
More informationCorrespondence should be addressed to Anas Khanfar;
Case Reports in Oncological Medicine, Article ID 949515, 4 pages http://dx.doi.org/10.1155/2014/949515 Case Report Durable Hematological and Major Cytogenetic Response in a Patient with Isolated 20q Deletion
More informationPreliminary Results From a Phase I Dose Escalation Trial of Ruxolitinib and the PI3Kδ Inhibitor TGR-1202 in Myelofibrosis
Preliminary Results From a Phase I Dose Escalation Trial of Ruxolitinib and the PI3Kδ Inhibitor TGR-1202 in Myelofibrosis Tamara K. Moyo, Andrew Sochacki, Gregory D. Ayers, Michael T. Byrne, Stephen A.
More informationHSCT for Myeloproliferative Disorders. Jane Apperley
HSCT for Myeloproliferative Disorders Jane Apperley Myeloproliferative disorders CML Polycythemia vera Essential thrombocythemia Primary myelofibrosis bcr-abl + bcr-abl - JAK2 (valine to phenylalanin an
More informationCLINICAL STUDY REPORT SYNOPSIS
CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-5412862:2.0 Research & Development, L.L.C. Protocol No.: R115777-AML-301 Title of Study: A Randomized Study of Tipifarnib Versus Best Supportive Care
More informationEuropean Focus on Myeloproliferative Diseases and Myelodysplastic Syndromes A critical reappraisal of anagrelide in the management of ET
European Focus on Myeloproliferative Diseases and Myelodysplastic Syndromes 2012 Clinical i l Aspects of Polycythemia and Essential Thrombocythemia A critical reappraisal of anagrelide in the management
More informationDisclosures for Ayalew Tefferi
Disclosures for Ayalew Tefferi Principal investigator role Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory Board Janssen, Geron, Celgene, Sanofi-Aventis, Gilead Sciences, Incyte
More informationPolycythemia Vera and Essential Thombocythemia A Single Institution Experience
INDIAN JOURNAL OF MEDICAL & PAEDIATRIC ONCOLOGY Vol. 29 No 4, 2008 7 Original Article-I Polycythemia Vera and Essential Thombocythemia A Single Institution Experience CECIL ROSS, NAVYA, VANAMALA AND KARUNA
More informationSWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL LEUKEMIA FORMS CHAPTER 16A REVISED: DECEMBER 2017
LEUKEMIA FORMS The guidelines and figures below are specific to Leukemia studies. The information in this manual does NOT represent a complete set of required forms for any leukemia study. Please refer
More informationORIGINAL ARTICLE. A Tefferi 1, TL Lasho 1, J Huang 1, C Finke 1, RA Mesa 1,CYLi 2,WWu 3, CA Hanson 2 and A Pardanani 1
(28) 22, 756 76 & 28 Nature Publishing Group All rights reserved 887-6924/8 $3. www.nature.com/leu ORIGINAL ARTICLE, compared to either a higher allele burden or unmutated status, is associated with inferior
More informationHow I treat high risk myeloproliferative neoplasms. Francesco Passamonti Università dell Insubria Varese - Italy
How I treat high risk myeloproliferative neoplasms Francesco Passamonti Università dell Insubria Varese - Italy How I treat high risk MF MF Treatment ELN 2018 Guidelines Anemia (Hb < 10 g/dl) Splenomegaly
More informationCME Information LEARNING OBJECTIVES
CME Information LEARNING OBJECTIVES Identify patients with MM who have undergone autologous stem cell transplant and would benefit from maintenance lenalidomide. Counsel older patients (age 65 or older)
More informationHow I Treat Myelofibrosis. Adam Mead, MD, PhD University of Oxford Oxford, United Kingdom
How I Treat Myelofibrosis Adam Mead, MD, PhD University of Oxford Oxford, United Kingdom Primary Myelofibrosis Archiv Fur Pathol. 1879;78:475-96. 2 cases of leukemia with peculiar blood and marrow findings
More informationManaging ET in Tiziano Barbui MD
Managing ET in 2019 Tiziano Barbui MD (tbarbui@asst-pg23.it) Hematology and Foundation for Clinical Research, Hospital Papa Giovanni XXIII Bergamo, Italy Managing ET in 2019 Establish diagnosis Risk Stratification
More informationThe BCR-ABL1 fusion. Epidemiology. At the center of advances in hematology and molecular medicine
At the center of advances in hematology and molecular medicine Philadelphia chromosome-positive chronic myeloid leukemia Robert E. Richard MD PhD rrichard@uw.edu robert.richard@va.gov Philadelphia chromosome
More informationEXPERIMENTAL AND THERAPEUTIC MEDICINE 9: , 2015
EXPERIMENTAL AND THERAPEUTIC MEDICINE 9: 1895-1900, 2015 Clinical characteristics of a group of patients with multiple myeloma who had two different λ light chains by immunofixation electrophoresis: A
More informationASH 2011 aktualijos: MSC TPŠL gydyme. Mindaugas Stoškus VULSK HOTC MRMS
ASH 2011 aktualijos: MSC TPŠL gydyme Mindaugas Stoškus VULSK HOTC MRMS #3042. Yukiyasu Ozawa et al. Mesenchymal Stem Cells As a Treatment for Steroid-Resistant Acute Graft Versus Host Disease (agvhd);
More informationCHALLENGING CASES PRESENTATION
CHALLENGING CASES PRESENTATION Michael C. Wiemann, MD, FACP Program Co-Chair and Vice President Indy Hematology Education President, Clinical St. John Providence Physician Network Detroit, Michigan 36
More informationJ Clin Oncol 29: by American Society of Clinical Oncology INTRODUCTION
VOLUME 29 NUMBER 4 FEBRUARY 1 11 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates
More informationTreatment of low risk MDS
Treatment of low risk MDS Matteo G Della Porta Cancer Center IRCCS Humanitas Research Hospital & Humanitas University Rozzano Milano, Italy matteo.della_porta@hunimed.eu International Prognostic Scoring
More informationEffect of Interleukin 10 on the Hematopoietic Progenitor Cells from Patients with Aplastic Anemia
Effect of Interleukin 10 on the Hematopoietic Progenitor Cells from Patients with Aplastic Anemia YOSHINOBU ASANO, SHOICHIRO SHIBATA, SHINJI KOBAYASHI, SEIICHI OKAMURA, YOSHIYUKI NIHO First Department
More informationMyelodysplastic syndrome (MDS) & Myeloproliferative neoplasms
Myelodysplastic syndrome (MDS) & Myeloproliferative neoplasms Myelodysplastic syndrome (MDS) A multipotent stem cell that can differentiate into any of the myeloid lineage cells (RBCs, granulocytes, megakaryocytes)
More informationASH 2014 Analyst & Investor Event
ASH 2014 Analyst & Investor Event December 8, 2014 John A. Scarlett, M.D. President & CEO, Geron Corporation Steven Lane, M.D., Ph.D. Queensland Institute of Medical Research Forward-Looking Statements
More informationPathology. #11 Acute Leukemias. Farah Banyhany. Dr. Sohaib Al- Khatib 23/2/16
35 Pathology #11 Acute Leukemias Farah Banyhany Dr. Sohaib Al- Khatib 23/2/16 1 Salam First of all, this tafreegh is NOT as long as you may think. If you just focus while studying this, everything will
More informationOverview of Aplastic Anemia. Overview of Aplastic Anemia. Epidemiology of aplastic anemia. Normal hematopoiesis 10/6/2017
Overview of Aplastic Anemia Overview of Aplastic Anemia Peter Westervelt, MD, PhD Professor of Medicine Chief, BMT/Leukemia Section Washington University School of Medicine Epidemiology Normal hematopoiesis
More informationHighest rates of thrombosis = age > 70, history of thrombosis, active disease (> 6 phlebotomies/yr) [2]
Polycythemia Vera Treatment Policy Prepared by Dr. Jeannie Callum Updated May 2003 Introduction PV is a chronic, clonal, myeloproliferative disorder, classically associated with an increase in red cell
More informationBlast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome
RESEARCH ARTICLE Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome AJH Mrinal M. Patnaik, 1 Emnet A. Wassie, 1 Terra L. Lasho, 2 Curtis
More informationLet s Look at Our Blood
Let s Look at Our Blood Casey O Connell, MD Associate Professor of Clinical Medicine Jane Anne Nohl Division of Hematology Keck School of Medicine of USC 10,000,000,000 WBCs/day Bone Marrow: The Blood
More informationTerapia del mieloma. La terapia di prima linea nel paziente giovane. Elena Zamagni
Terapia del mieloma La terapia di prima linea nel paziente giovane Elena Zamagni Istituto di Ematologia ed Oncologia Medica Seràgnoli Università degli Studi di Bologna Newly diagnosed MM Candidate for
More informationCurrent Prognostication in Primary Myelofibrosis
Current Prognostication in Primary Myelofibrosis Francisco Cervantes Hematology Department, Hospital Clínic, Barcelona, Spain Florence, April 2011 Survival in PMF No. patients: 1,054 Median Srv (95% CI):
More informationOutline. Case Study 5/17/2010. Treating Lower-Risk Myelodysplastic Syndrome (MDS) Tapan M. Kadia, MD Department of Leukemia MD Anderson Cancer Center
Treating Lower-Risk Myelodysplastic Syndrome (MDS) Tapan M. Kadia, MD Department of Leukemia MD Anderson Cancer Center Outline Case Study What is lower-risk MDS? Classification systems Prognosis Treatment
More informationOVERALL CLINICAL BENEFIT
noted that there are case reports of a rebound effect upon discontinuation of ruxolitinib (Tefferi 2012), although this was not observed in either the COMFORT I or COMFORT II studies. Therefore, perc considered
More informationOriginal article. Introduction
Original article Annals of Oncology 15: 134 138, 2004 DOI: 10.1093/annonc/mdh026 Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil):
More informationClassical Ph-1neg myeloproliferative neoplasms: Ruxolitinib in myelofibrosis. Francesco Passamonti Università degli Studi dell Insubria, Varese
Classical Ph-1neg myeloproliferative neoplasms: Ruxolitinib in myelofibrosis Francesco Passamonti Università degli Studi dell Insubria, Varese DIPSS during f-up IPSS at diagnosis Diagnose MF and genotype
More informationOpinion 9 January 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 9 January 2013 JAKAVI 5 mg, tablet Bottle of 60 tablets (CIP code : 2246225) JAKAVI 15 mg, tablet Bottle of 60 tablets
More informationShould lower-risk myelodysplastic syndrome patients be transplanted upfront? YES Ibrahim Yakoub-Agha France
Should lower-risk myelodysplastic syndrome patients be transplanted upfront? YES Ibrahim Yakoub-Agha France Myelodysplastic syndromes (MDS) are heterogeneous disorders that range from conditions with a
More informationTechnical Bulletin No. 100
CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 100 August 2, 2012 JAK2 AND MPL 515 MUTATIONAL ANALYSIS Contact: Dr. Jeffrey Wisotzkey, 717-851-1422 Technical Director, CPAL Jill A.
More informationTRANSPARENCY COMMITTEE OPINION. 14 February 2007
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 14 February 2007 GLIVEC 100 mg, capsule B/120 capsules (CIP: 358 493-5) GLIVEC 100 mg, capsule B/180 capsules (CIP:
More informationPOMALYST (pomalidomide) for Previously Treated Multiple Myeloma
POMALYST (pomalidomide) for Previously Treated What is POMALYST? POMALYST (pomalidomide) capsule is an oral immunomodulatory therapy (a thalidomide analogue) indicated for patients with multiple myeloma
More informationMyelodysplastic Syndrome Case 158
Myelodysplastic Syndrome Case 158 Dong Chen MD PhD Division of Hematopathology Mayo Clinic Clinical History 86 year old man Persistent borderline anemia and thrombocytopenia. His past medical history was
More information